PharmEasy FY26 Performance and IPO Update: From Heavy Losses to a Cleaner Balance Sheet

A few years ago, PharmEasy was known for fast growth, heavy discounts and big losses. FY26 tells a different story. The parent company, API Holdings, has put profitability ahead of growth, and the numbers are starting to show it. With its term debt now cleared, the IPO question is back in the market conversation.

Where PharmEasy came from

API Holdings is the parent of PharmEasy, but PharmEasy is only one part of the group. API Holdings also owns Thyrocare, Ascent and Aknamed, and PharmEasy is just the consumer pharmacy arm. The group has backing from large investors, including Temasek and TPG.

The company first tried to go public in 2022. It filed for a ₹6,250 crore IPO and then withdrew it in August 2022. Since then, the focus has moved from expansion to repair: fix the economics, cut the debt, and only then think about the market again.

FY26 financial performance

The headline numbers show a clear improvement in losses.

• Net loss: The consolidated net loss narrowed 67% to ₹520 crore in FY26, from ₹1,572 crore in FY25.
• Revenue: Revenue from operations was ₹6,618.50 crore, up 12.71% from ₹5,872.16 crore in FY25.
• Costs: Total expenses fell 0.9% to ₹7,146.7 crore.

The cost line is the most important one. Most companies need to spend more to grow. API Holdings grew revenue by double digits while keeping total spending flat. The nine-month trend pointed the same way. Revenue for 9M FY26 rose 14.7% to ₹5,095.5 crore. Over the same nine months, the loss before tax (excluding ESOP costs) narrowed to ₹350.9 crore from ₹565.7 crore a year earlier.

The company is still not profitable at the net level. FY26 PAT remained negative at ₹520.29 crore. The improvement is real, but the journey is not finished.

What changed inside the business

The shift began after Rahul Guha took over as CEO in August 2025. At that time, API Holdings carried roughly ₹1,800 crore of debt at interest rates above 20%. That kind of interest burden makes profit almost impossible, so the first job was to bring it down.

The operating changes were simple but tough. The company reduced discounts on the PharmEasy platform and in its distribution business, and exited hospital distribution contracts that were losing money. Giving up some revenue to stop losing money on each sale is the core of the new playbook.

The segments: B2B leads, B2C is catching up

The group's backbone is B2B pharma distribution. The segment earned ₹4,089 crore in FY26, growing 15% a year. It is a steady, volume-driven business, and it funds the rest of the group's ambitions.

The consumer app is smaller and still loss-making. In FY26, PharmEasy's consumer business generated ₹1,334.5 crore in revenue with an EBITDA loss of ₹44.1 crore. The trend is positive. In Q1 FY27, it recorded ₹347.9 crore in revenue with an EBITDA loss of ₹17 crore. If that pace continues, the consumer arm could reach break-even sooner than many expect, though the company has not promised a date.

Becoming debt-free

This is the biggest milestone of the year. API Holdings cleared the last ₹1,050 crore of its term debt by mid-August 2026, using internal cash and the sale of a 9.9% stake in Thyrocare. The group kept control of the diagnostics business, as it still holds 51.02% of the listed company.

A debt-free balance sheet means no heavy interest payments eating into earnings. It also helps in any future conversation with IPO investors. One point deserves clarity: "debt-free" here refers to term debt, not every liability the company may have.

The latest quarter

The momentum continued into Q1 FY27 (April to June 2026). API Holdings narrowed its loss to ₹29.6 crore from ₹145.4 crore a year earlier, and revenue rose 10% to ₹1,754 crore. EBITDA turned positive at ₹39.3 crore, against an EBITDA loss of ₹12.8 crore in the year-ago quarter. A positive EBITDA at the group level shows that day-to-day operations are now covering their own costs, before interest, tax and depreciation.

The IPO outlook

The IPO is not around the corner. Guha has been clear about his conditions: he wants to take a profitable company with zero or near-zero debt to the market, and said about a year of work remained. The company is targeting profitability by September 2027, after which it will decide between an IPO and a merger with Thyrocare. So the listing route is still open, but the timeline depends on the company meeting its own profit target first.

What to watch next

• Consumer business: whether the PharmEasy app keeps narrowing its EBITDA loss.

• Growth quality: whether revenue keeps rising now that discounts are lower.

• Net profit: how quickly the ₹520 crore loss shrinks further.

• Thyrocare: whether the group chooses a merger or keeps it as a separate listed arm.

• IPO timing: any update after the September 2027 profitability target.

Final take

API Holdings has done the hard part of a turnaround: cutting losses, clearing expensive debt and showing positive EBITDA in the latest quarter. The remaining steps are net profitability and a clear listing decision. For anyone tracking the unlisted shares, the story has moved from survival to execution.